Lantern Pharma Inc — Cash Flow (NASDAQ:LTRN) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities 5.65 M-10.59 M-12.77 M-14.35 M-17.81 M -16.86 M Cash from investing activities 16.14 K-19.53 M179.27 K-930.21 K3.37 M 16.21 M Cash from financing activities 23.66 M63.42 M-2.18 M-500 K66.71 K 971.78 K Free cash flow 5.65 M-10.59 M-12.8 M-14.37 M-17.83 M -16.86 M

Новости

FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas

Препарат LP-184 от Lantern показал перспективы в испытаниях фазы 1a

Lantern’s cancer drug LP-184 shows promise in phase 1a trial

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2025-11-15

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Disney, Brookfield, Nu Holdings and more set to report earnings Thursday

Акционеры Lantern Pharma избрали директоров и одобрили пересмотр цен опционов

Lantern Pharma shareholders elect directors and approve stock option repricing

Акции Lantern Pharma растут после достижения противораковым препаратом LP-184 целевых показателей в испытаниях

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints

Lantern Pharma receives FDA feedback on pediatric brain cancer trial